Spinal Muscular Atrophy Market - Global Outlook and Forecast 2022-2028

March 2022 | 61 pages | ID: S5C0CD806722EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Spinal Muscular Atrophy in Global, including the following market information:

Global Spinal Muscular Atrophy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Spinal Muscular Atrophy market was valued at 1285.7 million in 2021 and is projected to reach US$ 2540.8 million by 2028, at a CAGR of 10.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Early Stage Candidates Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Spinal Muscular Atrophy include Lonis Pharmaceuticals, F. Hoffmann-La Roche, AveXis, Novartis, Cytokinetics and Ionis Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spinal Muscular Atrophy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Spinal Muscular Atrophy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Spinal Muscular Atrophy Market Segment Percentages, by Type, 2021 (%)

• Early Stage Candidates
• Late Stage Candidates

Global Spinal Muscular Atrophy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Spinal Muscular Atrophy Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Spinal Muscular Atrophy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Spinal Muscular Atrophy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Spinal Muscular Atrophy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Spinal Muscular Atrophy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Lonis Pharmaceuticals
• F. Hoffmann-La Roche
• AveXis
• Novartis
• Cytokinetics
• Ionis Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Spinal Muscular Atrophy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Spinal Muscular Atrophy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL SPINAL MUSCULAR ATROPHY OVERALL MARKET SIZE

2.1 Global Spinal Muscular Atrophy Market Size: 2021 VS 2028
2.2 Global Spinal Muscular Atrophy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Spinal Muscular Atrophy Players in Global Market
3.2 Top Global Spinal Muscular Atrophy Companies Ranked by Revenue
3.3 Global Spinal Muscular Atrophy Revenue by Companies
3.4 Top 3 and Top 5 Spinal Muscular Atrophy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Spinal Muscular Atrophy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Spinal Muscular Atrophy Players in Global Market
  3.6.1 List of Global Tier 1 Spinal Muscular Atrophy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Spinal Muscular Atrophy Market Size Markets, 2021 & 2028
  4.1.2 Early Stage Candidates
  4.1.3 Late Stage Candidates
4.2 By Type - Global Spinal Muscular Atrophy Revenue & Forecasts
  4.2.1 By Type - Global Spinal Muscular Atrophy Revenue, 2017-2022
  4.2.2 By Type - Global Spinal Muscular Atrophy Revenue, 2023-2028
  4.2.3 By Type - Global Spinal Muscular Atrophy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Spinal Muscular Atrophy Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Spinal Muscular Atrophy Revenue & Forecasts
  5.2.1 By Application - Global Spinal Muscular Atrophy Revenue, 2017-2022
  5.2.2 By Application - Global Spinal Muscular Atrophy Revenue, 2023-2028
  5.2.3 By Application - Global Spinal Muscular Atrophy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Spinal Muscular Atrophy Market Size, 2021 & 2028
6.2 By Region - Global Spinal Muscular Atrophy Revenue & Forecasts
  6.2.1 By Region - Global Spinal Muscular Atrophy Revenue, 2017-2022
  6.2.2 By Region - Global Spinal Muscular Atrophy Revenue, 2023-2028
  6.2.3 By Region - Global Spinal Muscular Atrophy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Spinal Muscular Atrophy Revenue, 2017-2028
  6.3.2 US Spinal Muscular Atrophy Market Size, 2017-2028
  6.3.3 Canada Spinal Muscular Atrophy Market Size, 2017-2028
  6.3.4 Mexico Spinal Muscular Atrophy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Spinal Muscular Atrophy Revenue, 2017-2028
  6.4.2 Germany Spinal Muscular Atrophy Market Size, 2017-2028
  6.4.3 France Spinal Muscular Atrophy Market Size, 2017-2028
  6.4.4 U.K. Spinal Muscular Atrophy Market Size, 2017-2028
  6.4.5 Italy Spinal Muscular Atrophy Market Size, 2017-2028
  6.4.6 Russia Spinal Muscular Atrophy Market Size, 2017-2028
  6.4.7 Nordic Countries Spinal Muscular Atrophy Market Size, 2017-2028
  6.4.8 Benelux Spinal Muscular Atrophy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Spinal Muscular Atrophy Revenue, 2017-2028
  6.5.2 China Spinal Muscular Atrophy Market Size, 2017-2028
  6.5.3 Japan Spinal Muscular Atrophy Market Size, 2017-2028
  6.5.4 South Korea Spinal Muscular Atrophy Market Size, 2017-2028
  6.5.5 Southeast Asia Spinal Muscular Atrophy Market Size, 2017-2028
  6.5.6 India Spinal Muscular Atrophy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Spinal Muscular Atrophy Revenue, 2017-2028
  6.6.2 Brazil Spinal Muscular Atrophy Market Size, 2017-2028
  6.6.3 Argentina Spinal Muscular Atrophy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Spinal Muscular Atrophy Revenue, 2017-2028
  6.7.2 Turkey Spinal Muscular Atrophy Market Size, 2017-2028
  6.7.3 Israel Spinal Muscular Atrophy Market Size, 2017-2028
  6.7.4 Saudi Arabia Spinal Muscular Atrophy Market Size, 2017-2028
  6.7.5 UAE Spinal Muscular Atrophy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Lonis Pharmaceuticals
  7.1.1 Lonis Pharmaceuticals Corporate Summary
  7.1.2 Lonis Pharmaceuticals Business Overview
  7.1.3 Lonis Pharmaceuticals Spinal Muscular Atrophy Major Product Offerings
  7.1.4 Lonis Pharmaceuticals Spinal Muscular Atrophy Revenue in Global Market (2017-2022)
  7.1.5 Lonis Pharmaceuticals Key News
7.2 F. Hoffmann-La Roche
  7.2.1 F. Hoffmann-La Roche Corporate Summary
  7.2.2 F. Hoffmann-La Roche Business Overview
  7.2.3 F. Hoffmann-La Roche Spinal Muscular Atrophy Major Product Offerings
  7.2.4 F. Hoffmann-La Roche Spinal Muscular Atrophy Revenue in Global Market (2017-2022)
  7.2.5 F. Hoffmann-La Roche Key News
7.3 AveXis
  7.3.1 AveXis Corporate Summary
  7.3.2 AveXis Business Overview
  7.3.3 AveXis Spinal Muscular Atrophy Major Product Offerings
  7.3.4 AveXis Spinal Muscular Atrophy Revenue in Global Market (2017-2022)
  7.3.5 AveXis Key News
7.4 Novartis
  7.4.1 Novartis Corporate Summary
  7.4.2 Novartis Business Overview
  7.4.3 Novartis Spinal Muscular Atrophy Major Product Offerings
  7.4.4 Novartis Spinal Muscular Atrophy Revenue in Global Market (2017-2022)
  7.4.5 Novartis Key News
7.5 Cytokinetics
  7.5.1 Cytokinetics Corporate Summary
  7.5.2 Cytokinetics Business Overview
  7.5.3 Cytokinetics Spinal Muscular Atrophy Major Product Offerings
  7.5.4 Cytokinetics Spinal Muscular Atrophy Revenue in Global Market (2017-2022)
  7.5.5 Cytokinetics Key News
7.6 Ionis Pharmaceuticals
  7.6.1 Ionis Pharmaceuticals Corporate Summary
  7.6.2 Ionis Pharmaceuticals Business Overview
  7.6.3 Ionis Pharmaceuticals Spinal Muscular Atrophy Major Product Offerings
  7.6.4 Ionis Pharmaceuticals Spinal Muscular Atrophy Revenue in Global Market (2017-2022)
  7.6.5 Ionis Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Spinal Muscular Atrophy Market Opportunities & Trends in Global Market
Table 2. Spinal Muscular Atrophy Market Drivers in Global Market
Table 3. Spinal Muscular Atrophy Market Restraints in Global Market
Table 4. Key Players of Spinal Muscular Atrophy in Global Market
Table 5. Top Spinal Muscular Atrophy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Spinal Muscular Atrophy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Spinal Muscular Atrophy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Spinal Muscular Atrophy Product Type
Table 9. List of Global Tier 1 Spinal Muscular Atrophy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Spinal Muscular Atrophy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Spinal Muscular Atrophy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Spinal Muscular Atrophy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Spinal Muscular Atrophy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Spinal Muscular Atrophy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Spinal Muscular Atrophy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Spinal Muscular Atrophy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Spinal Muscular Atrophy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Spinal Muscular Atrophy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Spinal Muscular Atrophy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Spinal Muscular Atrophy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Spinal Muscular Atrophy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Spinal Muscular Atrophy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Spinal Muscular Atrophy Revenue, (US$, Mn), 2023-2028
Table 30. Lonis Pharmaceuticals Corporate Summary
Table 31. Lonis Pharmaceuticals Spinal Muscular Atrophy Product Offerings
Table 32. Lonis Pharmaceuticals Spinal Muscular Atrophy Revenue (US$, Mn), (2017-2022)
Table 33. F. Hoffmann-La Roche Corporate Summary
Table 34. F. Hoffmann-La Roche Spinal Muscular Atrophy Product Offerings
Table 35. F. Hoffmann-La Roche Spinal Muscular Atrophy Revenue (US$, Mn), (2017-2022)
Table 36. AveXis Corporate Summary
Table 37. AveXis Spinal Muscular Atrophy Product Offerings
Table 38. AveXis Spinal Muscular Atrophy Revenue (US$, Mn), (2017-2022)
Table 39. Novartis Corporate Summary
Table 40. Novartis Spinal Muscular Atrophy Product Offerings
Table 41. Novartis Spinal Muscular Atrophy Revenue (US$, Mn), (2017-2022)
Table 42. Cytokinetics Corporate Summary
Table 43. Cytokinetics Spinal Muscular Atrophy Product Offerings
Table 44. Cytokinetics Spinal Muscular Atrophy Revenue (US$, Mn), (2017-2022)
Table 45. Ionis Pharmaceuticals Corporate Summary
Table 46. Ionis Pharmaceuticals Spinal Muscular Atrophy Product Offerings
Table 47. Ionis Pharmaceuticals Spinal Muscular Atrophy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Spinal Muscular Atrophy Segment by Type in 2021
Figure 2. Spinal Muscular Atrophy Segment by Application in 2021
Figure 3. Global Spinal Muscular Atrophy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Spinal Muscular Atrophy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Spinal Muscular Atrophy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Spinal Muscular Atrophy Revenue in 2021
Figure 8. By Type - Global Spinal Muscular Atrophy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Spinal Muscular Atrophy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Spinal Muscular Atrophy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Spinal Muscular Atrophy Revenue Market Share, 2017-2028
Figure 12. US Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Spinal Muscular Atrophy Revenue Market Share, 2017-2028
Figure 16. Germany Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 17. France Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Spinal Muscular Atrophy Revenue Market Share, 2017-2028
Figure 24. China Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 28. India Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Spinal Muscular Atrophy Revenue Market Share, 2017-2028
Figure 30. Brazil Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Spinal Muscular Atrophy Revenue Market Share, 2017-2028
Figure 33. Turkey Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Spinal Muscular Atrophy Revenue, (US$, Mn), 2017-2028
Figure 37. Lonis Pharmaceuticals Spinal Muscular Atrophy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. F. Hoffmann-La Roche Spinal Muscular Atrophy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AveXis Spinal Muscular Atrophy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis Spinal Muscular Atrophy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Cytokinetics Spinal Muscular Atrophy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Ionis Pharmaceuticals Spinal Muscular Atrophy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)